Factors Influencing Adherence to Adjuvant Endocrine Therapy
NCT ID: NCT06192446
Last Updated: 2024-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2021-09-20
2024-09-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence
NCT01081509
Adherence Improving Self-Management Strategy (AIMS) in Breast Cancer Patients Using Adjuvant Endocrine Treatment (AET)
NCT04719455
Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Adherence and Clinical Outcome
NCT03761420
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
NCT02088710
Compliance to a Hormone Therapy Regimen in Breast Cancer
NCT00666822
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Women with hormone-sensitive early breast cancer
Women older than 18 years of age who have suffered from hormonally dependent breast cancer stages 0-III (from "in situ" to locally advanced breast cancer) according to the American Joint Committee on Cancer (AJCC) classification and have been undergoing adjuvant endocrine therapy for more than 3 months.
Survey using a questionnaire.
An observational study conducted in a cross-sectional manner using a questionnaire.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Survey using a questionnaire.
An observational study conducted in a cross-sectional manner using a questionnaire.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinical diagnosis of hormone receptor positive early breast cancer stages 0-III according to the American Joint Committee on Cancer (AJCC) classification
* prescribed with adjuvant endocrine therapy for more than 3 months
Exclusion Criteria
* other life-threatening illnesses
* mental disorders
* behavioral disorders caused by the use of psychoactive substances
* behavioral syndromes related to physiological disorders and physical factors
* cognitive impairment
* organic and symptomatic mental disorder
* schizophrenia
* disorders similar to schizophrenia
* delusional disorders
* personality disorders
* behavior disorders
* mental retardation
* psychological development disorders
* unspecified mental disorders
* Incapable of autonomously reaching decisions
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zagreb
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Iva Mucalo
Associate professor at the Center for Applied Pharmacy.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Zagreb Faculty of Pharmacy and Biochemistry
Zagreb, , Croatia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
380-130/134-22-4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.